We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

1 hedge funds and large institutions have $3.04M invested in CNS Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $1.98M → $3.04M (+$1.07M)

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$2.27M

Top Sellers

Rank Fund Capital Flow
1
ACM
Altium Capital Management
New York
-$951K
2
CH
CVI Holdings
Delaware
-$740K
3
WAM
Warberg Asset Management
Illinois
-$25K
4
CWAF
Core Wealth Advisors (Florida)
Florida
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$1.73M +$2.27M +1 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$336K – – –
Citadel Advisors
3
Citadel Advisors
Florida
$221K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$145K – – –
EIM
5
Essex Investment Management
Massachusetts
$142K – – –
Bank of New York Mellon
6
Bank of New York Mellon
New York
$104K – – –
VF
7
Virtu Financial
New York
$99K – – –
Northern Trust
8
Northern Trust
Illinois
$77K – – –
Jane Street
9
Jane Street
New York
$33K – – –
Wells Fargo
10
Wells Fargo
California
$33K – – –
Morgan Stanley
11
Morgan Stanley
New York
$30K – – –
Goldman Sachs
12
Goldman Sachs
New York
$28K – – –
ACI
13
Alpha Cubed Investments
California
$26K – – –
IAN
14
Integrated Advisors Network
Texas
$26K – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$12K – – –
UBS Group
16
UBS Group
Switzerland
$3K – – –
CAL
17
Capital Analysts LLC
Pennsylvania
$2K – – –
ACM
18
Altium Capital Management
New York
– -$951K -1 Closed
CWAF
19
Core Wealth Advisors (Florida)
Florida
– -$1K – –
CH
20
CVI Holdings
Delaware
– -$740K – –
WAM
21
Warberg Asset Management
Illinois
– -$25K – –

CNSP Hedge Fund Activity: Q1 2021 in Review

1 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q1 2021, worth a combined $3.04M — up 54% from $1.98M a quarter earlier.

Fund positioning in CNSP was balanced in Q1 2021: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.27M. The largest seller was Altium Capital Management, exiting entirely with an estimated $951K sold.

  • 1 institutional investor held CNS Pharmaceuticals (CNSP) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $3.04M of CNS Pharmaceuticals stock for Q1 2021, up 54% quarter-over-quarter.
  • 1 fund opened new CNS Pharmaceuticals positions in Q1 2021 and 1 closed out, a net change of 0 holders.
  • The largest CNS Pharmaceuticals buyer in Q1 2021 was Renaissance Technologies, an estimated $2.27M added.
  • The largest CNS Pharmaceuticals seller in Q1 2021 was Altium Capital Management, an estimated $951K sold.

Based on aggregated 13F filings for Q1 2021.